Fractyl Health, Inc. (GUTS)
- Previous Close
6.72 - Open
6.69 - Bid 6.65 x 400
- Ask 6.74 x 400
- Day's Range
6.47 - 6.84 - 52 Week Range
5.75 - 14.50 - Volume
111,785 - Avg. Volume
401,472 - Market Cap (intraday)
320.785M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.00
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
fractyl.comRecent News: GUTS
Compare To: GUTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUTS
Valuation Measures
Market Cap
320.78M
Enterprise Value
373.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.66k
Price/Book (mrq)
--
Enterprise Value/Revenue
3.12k
Enterprise Value/EBITDA
-7.40
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.33%
Return on Equity (ttm)
--
Revenue (ttm)
120k
Net Income Avi to Common (ttm)
-94.27M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
33.21M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-23.26M